Biotinylated Human CD58 Protein
Catalog No: CD58-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD58 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Phe29-Arg215 (accession: AAH05930).
Product Details
- Molecular Aliases
- Lymphocyte function-associated antigen 3; Ag3; CD58; LFA3
- Protein Length
- Phe29-Arg215
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 24.37 kDa. Due to glycosylation, the protein migrates to 35-58 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CD58 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CD58 is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human CD58, His Avi tag at 1μg/ml(100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human CD2, hFc Tag (Cat. CD2-HM202) with the EC50 of 2.6ng/ml determined by ELISA. (QC Test)
Loaded Biotinylated Human CD58, His-Avi tag on Steptavidin-Biosensor can bind Human CD2, hFc Tag (Cat. CD2-HM202) with an affinity constant of 6.46 nM as determined in BLI assay.
Background
Loss of CD58 is a common mechanism for tumor immune evasion in lymphoid malignancies. CD58 loss is known to occur due to both genetic and non-genetic causes; therefore, we hypothesized that restoring CD58 expression in lymphoma cells may be an effective treatment approach. EZH2 is involved in the epigenetic silencing of CD58 in lymphoma cells as a mechanism for tumor immune escape, and EZH2 inhibitors are able to restore epigenetically suppressed CD58 expression.
References
- Otsuka Y, Nishikori M, Arima H, Izumi K, Kitawaki T, Hishizawa M, Takaori-Kondo A. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas. Mol Immunol. 2020 Mar;119:35-45. doi: 10.1016/j.molimm.2020.01.006. Epub 2020 Jan 18. PMID: 31962268.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.